Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

NCT01110902 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

589

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Agomelatine (AGO178C)
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals